These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29530763)

  • 1. Switch from intravenous to subcutaneous abatacept: Our experience.
    Nieto-González JC; Ovalles-Bonilla JG; Estrada E; Monteagudo I
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):187-188. PubMed ID: 29530763
    [No Abstract]   [Full Text] [Related]  

  • 2. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
    D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
    Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
    Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
    Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
    Gupta R; Shipa M; Yeoh SA; Buck P; Ehrenstein MR
    Rheumatology (Oxford); 2021 Feb; 60(2):977-979. PubMed ID: 33232489
    [No Abstract]   [Full Text] [Related]  

  • 5. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
    Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
    J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
    Reggia R; Franceschini F; Tincani A; Cavazzana I
    J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
    Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
    Ariza R; Van Walsem A; Canal C; Roldán C; Betegón L; Oyagüez I; Janssen K
    Farm Hosp; 2014 Jul; 38(4):257-65. PubMed ID: 25137158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.
    Schiff M; Koo J; Jin E; Schiller E; Day A; Stevens R; Laskar C
    Adv Ther; 2016 Feb; 33(2):199-213. PubMed ID: 26833303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous abatacept in rheumatoid arthritis: current update.
    Keystone E; Alkhalaf A; Makkawy M
    Expert Opin Biol Ther; 2015; 15(8):1221-30. PubMed ID: 26160492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
    D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M;
    Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan.
    Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Eguchi M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Scand J Rheumatol; 2020 Jan; 49(1):13-17. PubMed ID: 31402744
    [No Abstract]   [Full Text] [Related]  

  • 15. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
    Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
    BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands.
    Kukida Y; Kasahara A; Seno T; Inoue T; Sagawa R; Kida T; Nakabayashi A; Nagahara H; Murakami K; Sugitani T; Morita S; Ito H; Oda R; Fujiwara H; Kohno M; Kawahito Y
    Int J Rheum Dis; 2018 Sep; 21(9):1678-1685. PubMed ID: 28730687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEXAS syndrome: favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up.
    Pathmanathan K; Taylor E; Balendra J; Lim A; Carroll G
    Rheumatology (Oxford); 2022 Jul; 61(7):e174-e177. PubMed ID: 35094047
    [No Abstract]   [Full Text] [Related]  

  • 20. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
    Keystone EC; Kremer JM; Russell A; Box J; Abud-Mendoza C; Elizondo MG; Luo A; Aranda R; Delaet I; Swanink R; Gujrathi S; Luggen M
    Ann Rheum Dis; 2012 Jun; 71(6):857-61. PubMed ID: 22302417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.